Prophylactic Mastectomy or Screening in Women Suspected to Have the BRCA1/2 Mutation

Abstract

Background. Women suspected to have the BRCA1/2 mutation may choose between two management options: breast cancer screening and prophylactic mastectomy (PM). Objectives. To compare women's treatment choices with medical and decision-analytic recommendations and to explore variables related to the women's choices. Methods. After provision of information, individual time-tradeoff values for the health outcome "living after PM" were assessed and incorporated into a decision-analytic model, which compared the management options PM and screening with respect to their effects on quality-adjusted life expectancy. Results. Of the 54 women suspected to have the mutation, 51 completed the shared-decision-making procedure. Quality-adjusted life expectancy after PM management was longer for 67% of proven carriers and for 58% of women awaiting the DNA-test result. Twelve proven carriers made definitive treatment choices: eight (67%) chose PM and four (33%) chose screening. All carriers' treatment choices agreed with the normative decision-analytic recommendations. Four (33%) disagreed with the medical recommendations. Of the 36 women awaiting DNA-test results, 32 made hypothetical treatment choices. The agreement between these hypothetical treatment choices and the decision-analytic recommendations was good (78%). Combining data from all 48 women, being married (OR = 14.00, p = 0.006), having children (OR = 4.71, p = 0.02), low desire to participate (OR = 0.14, p = 0.004), high decisional stress (OR = 5.22, p = 0.01), a lower estimate of the "probability of cure for screen-detected breast cancer" (OR = 0.13, p = 0.004), and higher time-tradeoff values for PM (OR = 182, p < 0.0001) made a choice for PM more likely. Conclusions. The complete agreement between the decision-analytic recommendations and the carriers' choices suggests that women act in accordance with normative decision theory. The disagreement between the carriers' choices and the medical recommendations suggests that women's choices and physicians' recommendations were guided by different arguments. The strong association between time-tradeoff value and treatment choice suggests that the time-tradeoff is a valid method to assess preferences. Key words: breast cancer; prophylactic mastectomy; screening; shared decision making, utilities; time preferences. (Med Decis Making 2000;20:251-262)

Get full access to this article

View all access options for this article.

References

Miki Y , Swensen J , Shattuck-Eidens D , et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.

Wooster R , Bignell G , Lancaster J , et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995,378 789-92.

Eeles RA , Stratton MR , Goldgar DE , Easton DF. The genetics of familial breast cancer and their practical implications. Eur J Cancer 1994,30A:1383-90.

Easton DF , Ford D , Bishop DT , the Breast Cancer Linkage Consortium.

Breast and ovarian cancer incidence in BRCA1-mutation carriers

Am J Hum Genet. 1995;56:265-71.

Struewing JP , Hartge P , Wacholder S , et al The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8

Ziegler LD , Kroll SS. Primary breast cancer after prophylactic mastectomy . Am J Clin Oncol 1991;14:451-4.

Pennisi VR , Capozzi A Subcutaneous mastectomy: an interim report on 1,244 patients. Ann Plast Surg. 1984;12:340-7.

Riolo Nemecek J , Young L , Lopez MJ.

Indications for prophylactic mastectomy

MO Med. 1993;90.136-40.

Houn F , Helzlsouer KJ , Friedman NB , Stefanek ME

The practice of prophylactic mastectomy: a survey of Maryland surgeons

Am J Public Health 1995,85.801-5.

10.

Bilimoria MM , Morrow M

The woman at increased risk for breast cancer evaluation and management strategies

Ca Cancer J Clin 1995;45:263-78.

11.

Stefanek ME , Helzlsouer KJ , Wilcox PM , Houn F.

Predictors of and satisfaction with bilateral prophylactic mastectomy

Prev Med 1995,24:412-9

12.

Burke W , Daly M , Garber J , et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer II BRCA1 and BRCA2 JAMA. 1997,277 997-1003

13.

Kerlikowske K , Grady D , Rubin SM , Sandrock C , Ernster VL

Efficacy of screening mammography A meta-analysis

JAMA 1995,273 149-54

14.

Kerlikowske K , Grady D , Barclay J , Sickles EA , Ernster VL

Effect of age, breast density, and family history on the sensitivity of first screening mammography

JAMA 1996;276:33-38

15.

Ma L , Fishell E , Wright B , Hanna W , Boyd NF Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst 1992;84.781-5

16.

Geel AN van, Rutgers EJT , Vos-Deckers GC , de Vries J , Wobbes T

Vrouwen met erfelijk risico op borstkanker consensus van chirurgische vertegenwoordigers van de werkgroepen voor erfelijke tumoren ten aanzien van intensieve controle, diagnostiek en preventieve ablatio

Ned Tijdschr Geneeskd . 1997,141.874-7

17.

McNeil BJ , Pauker SG , Sox HC , Tversky A

On the elicitation of preferences for alternative therapies

N Engl J Med 1982 , 306:1259-62

18.

Holmes MM , Rovner DR , Rothert ML , et al Women's and physicians' utilities for health outcomes in estrogen replacement therapy J Gen Intern Med. 1987 ;2:178-82

19.

Boyd NF , Sutherland HJ , Heasman KZ , Tritchler DL , Cummings BJ

Whose utilities for decision analysis

Med Decis Making. 1990,10:58-67

20.

Pauker SP , Pauker SG. The amniocentesis decision: ten years of decision analytic experience. Birth Defects 1987,3:151-69

21.

Verhoef LCG , Unic IJ , Stalmeier PFM , van Daal WAJ. Prophylactic mastectomy or screening for BRCA1/2 mutation carriers. a decision analysis using the tradeoffs of suspected carriers Manuscript under review

22.

Allais M The foundations of a positive theory of choice involving risk and criticism of the postulates and axioms of the American school In: Allais M , Hagen O (eds) Expected Utility Hypothesis and the Allais Paradox. Dordrecht, The Netherlands: D Reidel, 1979.27-145.

23.

Ubel PA , Loewenstein G The role of decision analysis in informed consent. choosing between intuition and systematicity. Soc Sci Med. 1997;44:647-56.

24.

Von Neumann J , Morgenstern O Theory of Games and Economic Behavior Princeton, NJ Princeton University Press , 1944

25.

Savage LJ The Foundations of Statistics. New York: Dover, 1954

26.

Samuelson PA Probability, utility, and the independence axiom. Econometrica 1952;20:670-8.

27.

27 Coombs CH , Dawes RM , Tversky A Mathematical Psychology: An Introduction . Englewood Cliffs, NJ: Prentice-Hall , 1970

28.

Unic I , Stalmeier PFM , Verhoef LCG , van Daal WAJ. Assessment of the time-tradeoff values for prophylactic mastectomy of women with a suspected genetic predisposition to breast cancer. Med Decis Making. 1998;18:268-77.

29.

Stalmeier PFM , Unic IJ , Verhoef LCG , van Daal WAJ Evaluation of a shared decision making program for women with suspected genetic predisposition for breast cancer. preliminary results. Medical Decis Making. 1999,19:230-41

30.

Froberg DG , Kane RL. Methodology for measuring health-state preferences II Scaling methods. J Clin Epidemiol 1989 ;42:459-71

31.

McNeil BJ , Weichselbaum R , Pauker SG

Speech and survival tradeoffs between quality and quantity of life in laryngeal cancer

N Engl J Med 1981;305 982-7.

32.

McNeil BJ , Weichselbaum R , Pauker SG Fallacy of the five-year survival in lung cancer. N Engl J Med 1978,299:1397-401

33.

Miyamoto JM , Eraker SA.

Parameter estimates for a QALY utility model

Med Decis Making 1985,5 191-213

34.

Verhoef LCG , Haan AFJ de , Daal WAJ van

Risk attitude in gambles with years of life empirical support for prospect theory

Med Decis Making 1994,14:194-200

35.

Sox HC , Blatt MA , Higgins MC , Marton KI Medical Decision Making. Boston, MA Butterworth, 1988.

36.

Easton DF , Bishop DT , Ford D , et al. Genetic linkage analysis in familial breast and ovarian cancer results from 214 families Am J Hum Genet. 1993;52:678-701

37.

Heckerling PS , Verp MS , Hadro TA.

Preferences of pregnant women for amniocentesis or chorionic villus sampling for prenatal testing comparison of patients' choices and those of a decision-analytic model

J Clin Epidemiol 1994,47 1215-28.

38.

Heckerling PS , Verp MS , Albert N

Patient or physician preferences for decision analysis. the prenatal genetic testing decision

Med Decis Making 1999;19:66-77.

39.

Elstein AS , Holzman GB , Ravitch MM , et al. Comparison of physicians' decisions regarding estrogen replacement therapy for menopausal women and decisions derived from a decision analytic model Am J Med 1986;80:246-58.

40.

McNeil BJ , Weichselbaum R , Pauker SG Fallacy of the five-year survival in lung cancer. N Engl J Med 1978,299.1397-401

41.

Pliskin JS , Shepard DS , Weinstein MC.

Utility functions for life years and health status

Operations Research. 1980;28: 206-24.

42.

Bechara A , Damasio H , Tranel D , Damasio AR. Deciding advantageously before knowing the advantageous strategy. Science. 1997;275:1293-5.

43.

Slovic P The construction of preference. Am Psychologist. 1995,50:364-71.

44.

Cohen BJ

Is expected utility theory normative for medical decision making?

Med Decis Making 1996;16:1-6.